Ascendis Pharma A/S

ASND

$225.60

Name : Ascendis Pharma A/S

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $14,840,728,576.00

EPSttm : 12.72

Ascendis Pharma A/S

$225.60

2.21%

$5.10

ASND — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

6.1

Margin Of Safety %

-9

Put/Call OI Ratio

0.58

EPS Next Q Diff

EPS Last/This Y

17.15

EPS This/Next Y

-3.18

Price

225.75

Target Price

311.51

Analyst Recom

1.1

Performance Q

-13.48

Upside

-24.4%

Beta

0.36

Ticker: ASND

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-08-28	ASND	248.07	0.49	2.68	7289
2026-08-31	ASND	263.25	0.52	0.14	7473
2026-09-02	ASND	267.56	0.47	0.09	8150
2026-09-03	ASND	271.24	0.46	0.58	8328
2026-09-04	ASND	270.63	0.47	0.39	8492
2026-09-08	ASND	270.42	0.46	0.05	8676
2026-09-09	ASND	261.03	0.45	1.70	8882
2026-09-10	ASND	261.2	0.46	4.56	8955
2026-09-11	ASND	264.18	0.48	0.03	9059
2026-09-14	ASND	264.56	0.47	0.41	9155
2026-09-15	ASND	239.89	0.47	0.86	9180
2026-09-16	ASND	247.69	0.49	1.39	10465
2026-09-17	ASND	239.12	0.51	0.73	10897
2026-09-18	ASND	236.72	0.49	1.61	10838
2026-09-21	ASND	237.19	0.58	0.06	8215
2026-09-22	ASND	237.5	0.56	0.46	8389
2026-09-23	ASND	223.36	0.55	0.65	8471
2026-09-24	ASND	230.88	0.58	0.65	10137
2026-09-25	ASND	225.95	0.58	0.70	10198
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-08-28	ASND	248.08	-	-	11.34
2026-08-31	ASND	263.12	-	68.2	11.34
2026-09-01	ASND	260.25	-	49.8	11.34
2026-09-02	ASND	267.48	-	634.6	11.34
2026-09-03	ASND	271.05	-	623.5	11.34
2026-09-04	ASND	270.71	-	610.5	11.34
2026-09-08	ASND	270.13	-	610.3	11.29
2026-09-09	ASND	261.13	-	584.7	11.29
2026-09-10	ASND	261.17	-	613.5	11.29
2026-09-11	ASND	264.10	-	621.8	11.29
2026-09-14	ASND	264.76	-	616.8	11.29
2026-09-15	ASND	239.77	-	533.8	12.77
2026-09-16	ASND	239.77	-	533.8	12.77
2026-09-17	ASND	239.10	-	583.9	12.75
2026-09-18	ASND	236.88	-	604.7	12.75
2026-09-21	ASND	237.51	-	615.3	12.75
2026-09-22	ASND	237.46	-	611.6	12.79
2026-09-23	ASND	223.15	-	560.2	12.79
2026-09-24	ASND	230.74	-	638.9	12.79
2026-09-25	ASND	225.75	-	591.6	12.79
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-08-28	ASND	-2.08	5.92	5.68
2026-08-31	ASND	-2.08	13.77	5.68
2026-09-01	ASND	-2.08	13.77	5.68
2026-09-02	ASND	-2.08	13.77	5.68
2026-09-03	ASND	-2.08	13.77	5.68
2026-09-04	ASND	-2.11	13.77	5.68
2026-09-08	ASND	-2.11	0.83	5.68
2026-09-09	ASND	-2.11	0.83	5.68
2026-09-10	ASND	-2.49	0.83	5.68
2026-09-11	ASND	-2.49	0.83	6.48
2026-09-14	ASND	-2.49	0.85	6.48
2026-09-15	ASND	-2.49	0.85	6.48
2026-09-16	ASND	-2.49	0.85	6.48
2026-09-17	ASND	-2.49	0.85	6.48
2026-09-18	ASND	-2.49	0.85	6.48
2026-09-21	ASND	-2.49	0.93	6.48
2026-09-23	ASND	-2.49	0.93	6.48
2026-09-24	ASND	-2.49	0.93	6.48
2026-09-25	ASND	-2.49	0.93	6.10
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

0.94

Avg. EPS Est. Next Quarter

1.16

Insider Transactions

-2.49

Institutional Transactions

0.93

Beta

0.36

Average Sales Estimate Current Quarter

364

Average Sales Estimate Next Quarter

411

Fair Value

205.9

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

311.51

P/E

17.19

Forward P/E

21.68

PEG

P/S

12.14

P/B

9.02

P/Free Cash Flow

38.1

EPS

13.12

Average EPS Est. Cur. Y

12.79

EPS Next Y. (Est.)

9.62

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

70.99

Relative Volume

0.55

Return on Equity vs Sector %

25.4

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

1.45

EBIT Estimation

591.6

◆ ASND Healthcare

$225.60

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

20/20

Pullback

23/25

Volume

8/15

Valuation

17/20

TP/AR

2/10

Options

5/10

RSI

34.9

Range 1M

12.3%

Sup Dist

0.9%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

13/25

Growth

19/30

Estimates

3/20

Inst/Vol

4/15

Options

6/10

EPS Yr

475.3%

EPS NY

-35.2%

52W%

42.3%

💎

Long-Term Value

Quality companies, undervalued

WATCH

🔴 SELL -17.3% upside

Quality

30/30

Valuation

4/30

Growth

11/25

Stability

7/10

LT Trend

3/5

Upside

-17.3%

Quality

MoS

-9%

ASND — P/E HistoricalBiotechnology

Ascendis Pharma A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 1189

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

ASND

Latest News

—

Caricamento notizie per ASND…

stock quote shares ASND – Ascendis Pharma A/S Stock Price stock today

news today ASND – Ascendis Pharma A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch ASND – Ascendis Pharma A/S yahoo finance google finance

stock history ASND – Ascendis Pharma A/S invest stock market

stock prices ASND premarket after hours

ticker ASND fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ASND

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y